Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Accelerate Diagnostics (NASDAQ:AXDX) reported Q1 2024 GAAP EPS of $(0.88), missing the $(0.72) estimate, with sales of $2.921M also missing the $3.000M estimate. Despite these misses, both losses and sales showed improvement over the previous year.

May 08, 2024 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Accelerate Diagnostics reported a larger than expected quarterly loss and a slight miss in sales, but showed improvement over the previous year.
The miss in both EPS and sales estimates is likely to negatively impact investor sentiment in the short term, despite the year-over-year improvements. Typically, earnings misses can lead to a decrease in stock price as they may signal operational challenges or lower than expected growth. However, the improvement over the previous year's performance might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100